These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 36054582)
41. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China. Lv J; Zhang H; Zhou Y; Li G; Zou W; Wang H Nephrology (Carlton); 2008 Jun; 13(3):242-6. PubMed ID: 18221258 [TBL] [Abstract][Full Text] [Related]
42. Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. Basset M; Milani P; Ferretti VV; Nuvolone M; Foli A; Benigna F; Nanci M; Bozzola M; Ripepi J; Sesta M; Russo F; Bosoni T; Klersy C; Albertini R; Merlini G; Palladini G Clin Chem Lab Med; 2022 Feb; 60(3):386-393. PubMed ID: 35018751 [TBL] [Abstract][Full Text] [Related]
43. Primary amyloidosis of the kidney. Shafique S; Wetmore J; Almehmi A W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306 [TBL] [Abstract][Full Text] [Related]
44. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. Gertz MA; Dispenzieri A JAMA; 2020 Jul; 324(1):79-89. PubMed ID: 32633805 [TBL] [Abstract][Full Text] [Related]
45. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. Angel-Korman A; Jaberi A; Sanchorawala V; Havasi A Amyloid; 2020 Mar; 27(1):17-24. PubMed ID: 31595786 [No Abstract] [Full Text] [Related]
46. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Janssens P; Van Hoeve K; De Waele L; De Rechter S; Claes KJ; Van de Perre E; Wissing KM; Bammens B; Jansen A; Mekahli D Pediatr Nephrol; 2018 Nov; 33(11):2085-2093. PubMed ID: 29987458 [TBL] [Abstract][Full Text] [Related]
47. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972 [TBL] [Abstract][Full Text] [Related]
48. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis]. Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633 [No Abstract] [Full Text] [Related]
49. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045 [TBL] [Abstract][Full Text] [Related]
50. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Peters HP; Waanders F; Meijer E; van den Brand J; Steenbergen EJ; van Goor H; Wetzels JF Nephrol Dial Transplant; 2011 Nov; 26(11):3581-8. PubMed ID: 21467131 [TBL] [Abstract][Full Text] [Related]
51. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Gertz MA Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180 [TBL] [Abstract][Full Text] [Related]
52. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Kastritis E; Papassotiriou I; Merlini G; Milani P; Terpos E; Basset M; Akalestos A; Russo F; Psimenou E; Apostolakou F; Roussou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas DC; Papadopoulou E; Pamboucas C; Dimopoulos MA; Palladini G Blood; 2018 Apr; 131(14):1568-1575. PubMed ID: 29386197 [TBL] [Abstract][Full Text] [Related]